Challenges of using natriuretic peptides to screen for the risk of developing heart failure in patients with diabetes: a report from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Clinical Applications
These suggestions for diabetes eventually will include others at high risk. They will require close attention to the issues involved in measuring and interpreting NP values.
Authors
- Kristin M. Aakre (ORCID: https://orcid.org/0000-0002-7340-6736)
- Nicholas L. Mills (ORCID: https://orcid.org/0000-0003-0533-7991)
- Torbjørn Omland (ORCID: https://orcid.org/0000-0002-6452-0369)
- Allan S. Jaffe (ORCID: https://orcid.org/0000-0003-1183-3959)
- Yader Sandoval
Institutions
- Abbott Northwestern Hospital (US)
- Mayo Clinic (US)
- University of Oslo (NO)
- Akershus University Hospital (NO)
- Haukeland University Hospital (NO)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- University of Bergen (NO)
- University of Edinburgh (GB)
Publication Details
- Journal
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1515/cclm-2025-0863
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00